DPP4 and Hypoglycemia: Data derived from randomized controlled trials (RCTs) have unequivocally demonstrated that dipeptidyl peptidase 4 (DPP-4) inhibitors mitigate levels of glycated hemoglobin (HbA1c),6,7 do not impact body weight,6 present a diminished risk of hypoglycemia,8,9 and do not escalate the likelihood of cardiovascular incidents.10, 11, 12, 13